Podcast
Monty Pal
At the Crossroads of Cancer and Metabolism
Clips
Summary
Dr. Charles Brenner explores the metabolic links between cancer, diabetes, NAD, and the future of liver-focused therapies.
In this episode of On the Edge of Breakthrough, host Dr. Monty Pal sits down with Dr. Charles Brenner, an internationally recognized expert in metabolism and the founding Chair of the Department of Diabetes & Cancer Metabolism at City of Hope. Together, they explore the metabolic links between diabetes, obesity, and cancer, and how understanding those connections could lead to new ways to prevent and treat multiple diseases.
Dr. Brenner shares insights from his research into lean fatty liver disease (otherwise known as metabolic dysfunction-associated steatotic liver disease or MASLD), and how certain genetic factors may be quietly driving both metabolic dysfunction and cancer risk. They also discuss the rise of GLP-1 therapies and how a new class of compounds targeting FGF21 might offer a potential new therapeutic option that could help curb sugar cravings and support liver health.
This episode takes listeners deep into the science of energy balance, NAD metabolism, fatty liver disease, and what it truly means to be on the edge of a breakthrough.
Related Topics
You May Also Like
Monty Pal
Podcast
Monty Pal
Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.
Article
Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
Article
Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer
Value assessment of oncology drugs using a weighted criterion-based approach
Article
Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
Article
Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD